20s Proteasome Pipeline Review, H1 2018
Summary
According to the recently published report '20s Proteasome Pipeline Review, H1 2018'; 20s Proteasome pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
20s Proteasome 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex.
The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATPdependent manner, the 20S proteasome is ATPindependent and only degrades entirely unfolded polypeptides.
The report '20s Proteasome Pipeline Review, H1 2018' outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 1 and 2 respectively.
Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Non Malignant Disorders and Women's Health which include indications Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Gynecological Cancer, Waldenstrom Macroglobulinemia, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Amyloidosis, Breast Cancer, Chronic Lymphocytic Leukemia CLL, Colon Cancer, Cutaneous TCell Lymphoma, Diffuse Large BCell Lymphoma, Endometriosis, Glioblastoma Multiforme GBM, Gliosarcoma, Hematological Tumor, Kidney Transplant Rejection, Lymphoma, Malignant Glioma, Mantle Cell Lymphoma, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Multiple Myeloma Kahler Disease, Neuroendocrine Cancer, NonSmall Cell Lung Cancer, Ovarian Cancer, Peripheral TCell Lymphomas PTCL, Prostate Cancer, Renal Cell Carcinoma, Skin Cancer, SmallCell Lung Cancer, Solid Tumor, TCell Lymphomas, Tuberculosis and Uterine Leiomyoma Uterine Fibroids.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for 20s Proteasome
The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects
The report assesses 20s Proteasome targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to 20s Proteasome targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for 20s Proteasome
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope